

Research Article

Unmasking Snake Venom of *Bothrops leucurus*: Purification and Pharmacological and Structural Characterization of New PLA₂ Bleu TX-III

Fábio André Marangoni,¹ Luis Alberto Ponce-Soto,²
Sergio Marangoni,² and Elen Cristina Teizem Landucci¹

¹ Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, 13083-970 Campinas, SP, Brazil

² Department of Biochemistry, Institute of Biology, State University of Campinas, 13083-970 Campinas, SP, Brazil

Correspondence should be addressed to Luis Alberto Ponce-Soto; poncesoto@yahoo.com.ar

Received 4 September 2012; Revised 31 October 2012; Accepted 6 November 2012

Academic Editor: Laura Leiva

Copyright © 2013 Fábio André Marangoni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Bleu TX-III was isolated from *Bothrops leucurus* snake venom on one-step analytical chromatography reverse phase HPLC, was homogeneous on SDS-PAGE, and was confirmed by Q-ToF Ultima API ESI/MS (TOF MS mode) mass spectrometry in 14243.8 Da. Multiple alignments of Bleu TX-III show high degree of homology with basic PLA₂ myotoxins from other *Bothrops* venoms. Our studies on local and systemic myotoxicity “*in vivo*” reveal that Bleu TX-III is myotoxin with local but not systemic action due to the decrease in the plasmatic CK levels when Bleu TX-III is administrated by intravenous route in mice (dose 1 and 5 µg). And at a dose of 20 µg myotoxin behaves like a local and systemic action. Bleu TX-III induced moderate marked paw edema, evidencing the local increase in vascular permeability. The inflammatory events induced in the mice (I.M.) were investigated. The increase in the levels of IL-1, IL-6, and TNF-α was observed in the plasma. It is concluded that Bleu TX-III induces inflammatory events in this model. The enzymatic phospholipid hydrolysis may be relevant to these phenomena. *Bothrops leucurus* venom is still not extensively explored, and the knowledge of its toxins separately through the study of structure/function will contribute for a better understanding of its action mechanism.

1. Introduction

Snake venom contains a mixture of powerful proteins and peptides that have evolved to be targeted to receptors, ion channels, or enzymes [1], in addition to some carbohydrates, nucleosides, lipids, and metal ions, whose functions are not all known [2, 3]. They interact with a wide variety of mammalian proteins and can disrupt the central and peripheral nervous systems, the blood coagulation cascade, the cardiovascular and neuromuscular systems, and homeostasis in general. These venom proteins act with great precision different toxins recognize different subtypes of certain receptors with only subtle differences and are very biologically active.

Phospholipases A₂ (PLA₂, EC 3.1.1.4) are generally Ca²⁺-dependent enzymes that catalyze the hydrolysis of the sn-2

fatty acyl bond of glycerophospholipids. Secreted PLA₂s are small proteins (14–18 kDa) usually containing 5–8 disulfide bonds and possessing a His/Asp dyad required for catalysis. Snake venom PLA₂s are classified into groups I or II, based on their sequence and mode of disulphide pairings. Group I PLA₂s are found in the venoms of Elapidae snakes, whereas group II PLA₂s are present in the venoms of Viperidae snakes [4]. The group II is further divided into two main subgroups: Asp49 and Lys49 (PLA₂ homologues) variants. In the latter, the aspartic acid residue at position 49, critically involved in calcium binding and essential for catalytic activity, is replaced by lysine. Due to this and other critical substitutions, the Lys49 PLA₂s cannot bind calcium efficiently and are considered to be enzymatically inactive [5, 6]. Although catalytic activity has been shown to play a role in the toxic actions of some venom PLA₂s, it is not essential in the case of

Lys49 PLA₂s, which use nonenzymatic mechanisms to alter membrane homeostasis [6].

Several PLA₂s have been identified from *Bothrops leucurus* venom including one acidic [7], one basic phospholipase A₂ and phospholipase A₂ homologous K49 [8]. This diversity of PLA₂, found in the venom of *Bothrops leucurus*, agrees with studies that show marked ontogenetic and individual venom variations [1].

In the present work, a new basic PLA₂ (Bleu TX-III) from the venom of *Bothrops leucurus* has been isolated and characterized, in order to obtain insights into its possible biological roles and its relevance to the pathophysiology of envenomings by this species in the north-eastern Brazil.

2. Material and Methods

2.1. Reverse Phase HPLC. The PLA₂ (Bleu TX-III) from *Bothrops leucurus* snake venom was purified by reverse phase HPLC according to method described by Ponce-Soto et al. [9]. Briefly, 5 mg of whole venom was dissolved in 100 μ L of buffer A (0.1% TFA) and 150 μ L NH₄HCO₃ 50 mM and centrifuged at 4500 g, and the supernatant was then applied on the analytical reverse phase HPLC μ -Bondapak C-18, previously equilibrated with buffer A for 15 min. The elution of the protein was then conducted using a linear gradient of buffer B (66.5% Acetonitrile in buffer A), and the chromatographic run was monitored at 280 nm of absorbance. After elution the fraction was lyophilized and stored at 40°C.

2.2. Electrophoresis. Tricine SDS-PAGE in a discontinuous gel and buffer system was used to estimate the molecular mass of the proteins, under reducing and nonreducing conditions [10].

2.3. PLA₂ Activity. PLA₂ activity was measured using the assay described [11] modified for 96-well plates [12]. The standard assay mixture contained 200 μ L of buffer (10 mM Tris-HCl, 10 mM CaCl₂, and 100 mM NaCl, pH 8.0), 20 μ L of substrate (3 mM), 20 μ L of water and 20 μ L of PLA₂ (1 mg/mL) in a final volume of 260 μ L. After adding PLA₂ (Bleu TX-III) from *Bothrops leucurus* (20 μ g), the mixture was incubated for up to 40 min at 37°C, with the reading of absorbance at intervals of 10 min. The enzyme activity, expressed as the initial velocity of the reaction (V_o), was calculated based on the increase of absorbance after 20 min. All assays were done in triplicate, and the absorbances at 425 nm were measured with a VersaMax 190 multiwell plate reader (Molecular Devices, Sunnyvale, CA, USA).

2.4. Amino Acid Analysis. Amino acid analysis was performed on a Pico-Tag Analyzer (Waters Systems) as described [13]. The PLA₂ (Bleu TX-III) from *Bothrops leucurus*, sample (30 μ g), was hydrolyzed at 105°C for 24 h, in 6 M HCl (Pierce sequencing grade) containing 1% phenol (w/v). The hydrolyzates were reacted with 20 μ L of derivatization solution (ethanol:triethylamine:water:phenylisothiocyanate, 7:1:1:1, v/v) for 1 h at room temperature, after which the PTC-amino acids were identified

and quantified by HPLC, by comparing their retention times and peak areas with those from a standard amino acid mixture.

2.5. Mass Spectrometry. An aliquot (4.5 μ L) of the modified proteins was injected in C18 (100 μ m \times 100 mm) RP-UPLC (nanoAcquity UPLC, Waters) coupled with nanoelectrospray tandem mass spectrometry on a Q-ToF Ultima API mass spectrometer (MicroMass/Waters) at a flow rate of 600 nl/min. The gradient was 0–50% acetonitrile in 0.1% formic acid over 45 min. The instrument was operated in MS continuum mode, and the data acquisition was from m/z 100–3,000 at a scan rate of 1 s and an interscan delay of 0.1 s. The spectra were accumulated over about 300 scans and the multiple charged data by the mass spectrometer on the m/z scale were converted to the mass (molecular weight) scale using Maximum Entropy-based software supplied with Masslynx 4.1 software package. The processing parameters were output mass range 6,000–20,000 Da at a “resolution” of 0.1 Da/channel; the simulated isotope pattern model was used with the spectrum blur width parameter set to 0.2 Da, the minimum intensity ratios between successive peaks were 20% (left and right). The deconvoluted spectrum was then smoothed (2 \times 3 channels, Savitzky Golay smooth) and the mass centroid values obtained using 80% of the peak top and a minimum peak width at half height of 4 channels.

2.6. Myotoxic Activity. Groups of four Swiss mice (18–20 g) received an intramuscular (i.m.) or an intravenous (i.v.) injection of variable amounts of PLA₂ (Bleu TX-III) from *Bothrops leucurus* in 100 μ L of PBS, in the gastrocnemius. A control group received 100 μ L of PBS. At different intervals of time (2, 4, 6, 9, and 24 h) blood was collected from the tail into heparinized capillary tubes, and the plasma creatine kinase (CK; EC 2.7.3.2) activity was determined by a kinetic assay (Sigma 47-UV). Activity was expressed in U/L, one unit defined as the phosphorylation of 1 μ mol of creatine/min at 25°C.

2.7. Edema-Forming Activity. The ability of PLA₂ (Bleu TX-III) from *Bothrops leucurus* to induce edema was studied in groups of five Swiss mice (18–20 g). 50 μ L of phosphate-buffered saline (PBS; 0.12 M NaCl, 0.04 M sodium phosphate, pH 7.2) with venom (10 μ g/paw) was injected in the subplantar region of the right footpad. The control group received an equal volume of PBS alone. The swelling of the paw was measured at 0.5, 1, 3, 6, 9, and 24 h after administration. Edema was expressed as the percentage increased in the volume of the treated group to that of the control group at each time interval.

2.8. Cytokines. The levels of cytokines IL-6 and IL-1 in the serum from BALB/c mice were assayed by a two-site sandwich enzyme-like immunosorbent assay (ELISA) as described [14]. In brief, ELISA plates were coated with 100 μ L (1 μ g/mL) of the monoclonal antibodies anti-IL-6 and anti-IL-1. In 0.1 M sodium carbonate buffer (pH 8.2) and incubated for 6 hours at room temperature. The

wells were then washed with 0.1% phosphate-buffered saline (PBS/Tween-20) and blocked with 100 μ L of 10% fetal calf serum (FCS) in PBS for 2 hours at room temperature. After washing, duplicate sera samples of 50 μ L were added to each well. After 18 hours of incubation at 4°C, the wells were washed and incubated with 100 μ L (2 μ g/mL) of the biotinylated monoclonal antibodies anti-IL-6 and anti-IL-1 as second antibodies for 45 minutes at room temperature. After a final wash, the reaction was developed by the addition of orthophenyldiamine (OPD) to each well. Optical densities were measured at 405 nm in a microplate reader. The cytokine content of each sample was read from a standard curve established with the appropriate recombinant cytokines (expressed in picograms per millilitre). The minimum levels of each cytokine detectable in the conditions of the assays were 10 pg/mL for IL-6 and IL-1.

To measure the cytotoxicity of TNF- α present in the serum from BALB/c mice, a standard assay with L-929 cells, a fibroblast continuous cell line was used as described previously [15]. The percentage cytotoxicity was calculated as follows:

$$\left(A_{\text{control}} - \frac{A_{\text{sample}}}{A_{\text{control}}} \right) \times 100. \quad (1)$$

Titres were calculated as the reciprocal of the dilution of the sample in which 50% of the cells in the monolayer were lysed. TNF- α activity is expressed as units/mL, estimated from the ratio of a 50% cytotoxic dose of the test to that of the standard mouse recombinant TNF- α .

2.9. Statistical Analyses. Results were reported as mean \pm SEM. The significance of differences among means was assessed by analysis of variance followed by Dunnett's test when several experimental groups were compared with the control group. Differences were considered statistically significant if $P < 0.05$.

3. Results

The elution profile of *Bothrops leucurus* venom following RP-HPLC performed on a C18 column showed thirteen fractions (1–12) (Figure 1(a)). The five eluted peaks were screened for PLA₂ activity. Only the fraction labeled in Figure 1(a) presented PLA₂ activity, which was eluted with 59% of buffer B. This peak was further purified by the same chromatography system used in the first fractionation step (RP-HPLC). The result of the repurification showed the presence of only one peak, named Bleu TX-III (Figure 1(a) inserted).

The Q-ToF Ultima API ESI/MS (TOF MS mode) mass spectrometry analysis confirmed the homogeneity of the fraction Bleu TX-III and determined the exact molecular mass of 14243, 4297 Da (Figure 1(b)). This value of molecular mass was used in calculating the molar concentrations of toxin used in the experiments described below.

The amino acid composition determined was D/11, T/9, S/7, E/9, P/4, G/11, A/5, C/14, V/4, M/3, I/5, L/7, Y/11, F/5, K/7, H/3 e R/10, W/Not determined.

TABLE 1: Sequence obtained by ESI-MS/MS based on the alkylated tryptic peptides derived. The peptide were separated and sequenced by mass spectrometry.

Residue Number	Mass (Da) expected	Amino acid sequence	Mass (Da) calculated
1–11	1377.6510	DLWQFGKMILK	1377.7479
8–15	918.4353	MILKETGK	918.5208
43–53	1504.4404	CCFVHDCCYGK	1504.5356
61–68	1046.4846	TDRYSYSR	1046.4781
69–82	1520.6066	ENGDVVCGGDDPCK	1520.5872
98–106	1110.4915	DNKDTYDIK	1110.5193
107–113	933.4279	YWFYGAKE	933.4385

The PLA₂ activity was examined in the *Bothrops leucurus* venom and in Bleu TX-III using the synthetic substrate 4-nitro-3 (octanoyloxy) benzoic. The PLA₂ activity was higher in Bleu TX-III (16,22 \pm 0,5268 nmols/mim/mg) and P4 (*b/D*-PLA₂) (15,728 \pm 0,3354 nmols/mim/mg), when compared with fraction 2 (*P3 b/K*-PLA₂) (2,856 \pm 0,464 nmols/mim/mg), and the whole venom (3,617 \pm 0,4144 nmols/min/mg) (Figure 1(c)).

The alkylated protein Bleu TX-III was digested separately with trypsin, and the resulting tryptic peptides were fractionated by RP-HPLC. Each peak numbered in the chromatogram (data not shown) was manually collected and lyophilized, and sequencing of the peptide was done by ESI mass spectrometry. Isoleucine and leucine residues were not discriminated in any of the sequences reported since they were indistinguishable in the low-energy CID spectra. Due to the external calibration applied to all spectra, it was also not possible to resolve the 0.036 Da difference between the glutamine and lysine residues, except for the lysine that was deduced based on the cleavage and missed cleavage of the enzyme.

The deduced sequence and measured masses of alkylated peptides of Bleu TX-III are summarized in Table 1; on the basis of sequence determination, 9 peptides were finding in the protein. The sequence of each peptide was then submitted separately to the NCBI database using the protein search program BLAST-p. Using the position matches of the sequenced peptides with homologous proteins present in the database, it was possible to deduce their original position on the unknown protein Bleu TX-III.

The sequence of those proteins returns high homology with the sequence of a phospholipase A₂ present in the venom of *Crotalus scutulatus scutulatus* (Mojave rattlesnake) (PA2B_CROSS Accession Number P62023; [16]). The partial Bleu TX-III sequence obtained was then resubmitted to BLAST-p, with the search restricted to Crotalinae snakes. Figure 3 shows the result of BLAST alignment between Bleu TX-III with the phospholipase A₂ from human pancreatic (0910150a) [17] and other PLA₂ coming from the venom of snakes of the family Viperidae. P62023 Mtx-b PLA₂ of *Crotalus scutulatus scutulatus* [16]; P0C942_1a LmTX-I de *Lachesis muta muta* [5] and P0C8M1 BmTX-I of *Bothrops moojeni* [18].




FIGURE 1: (a) Elution profile of *Bothrops leucurus* venom by RP-HPLC on a μ -Bondapak C18 column. *Fraction 5 (PLA₂ Bleu TX-III) contained PLA₂ and myotoxic activity. Insert: rechromatography on RP-HPLC of Bleu TX-III. (b) PLA₂ activity of *Bothrops leucurus* venom, b/K49, b/D49 [8], and PLA₂ Bleu TX-III. The results of all experiments are the mean \pm SEM of three determinations ($P < 0.05$). (c) Mass determination of the native Bleu TX-III by Q-ToF Ultima API ESI/MS (TOF MS mode) mass spectrometry. Insert electrophoretic profile in Tricine SDS-PAGE. (d) Raw electrospray-positive mass spectrum, showing multicharged ions distributions of native Bleu TX-III.

The sequence coverage was high for Bleu TX-III; the protein shared the conserved sequence domains common to this group of proteins, including the 14 cysteines, the calcium-binding site located on Gly30, Gly32, Tyr28, and Asp49, together with the amino acid of active site His48 (SwissProt database <http://br.expasy.org/>). The tandem mass spectra shown in Figure 2, relative to the peptide eluted in fraction 3 of both digest, having the sequence KCCFVHDCCYG, allow to classify both enzymes as PLA₂. *In vivo*, the Bleu TX-III induced a visible local myotoxic when injected by the i.m. route (Figure 4(a)), but with a regular increase in plasma levels of CK occurred after IV injection in single dose

of 20 μ g. Time-course analysis showed a maximum increase in plasma CK 3 hours after i.m. injection, returning to normal by 24 h (Figure 4(b)).

Bleu TX-III also induced moderate footpad edema, with a MED of 5 ± 2 μ g, evidencing the local increase in vascular permeability. Edema reached its highest point after 3 h, rapidly returning to basal levels thereafter (Figure 4(c)).

To further analyse and compare the mechanisms of the inflammatory events induced by PLA₂ Bleu TX-III, the concentrations of IL-1, IL-6, and TNF- α in the plasma were measured. Bleu TX-III caused a marked increase in levels of both IL-1 and IL-6, 1, 3, and 6 hours, peaking at 6 hours




FIGURE 4: (a) and (b) Time-course of the increments in plasma CK activity after intramuscular injection and intravenous of Bleu TX-III PLA₂ (1, 5, and 20 μg). Controls were injected with 100 μL of PBS. At different times, blood was collected, and serum levels were measured. Values are means ± SEM of five mice at each time point. (c) Edema-forming activity of Bleu TX-III PLA₂ (1, 5 and 20 μg). In mice. Induction of edema by Bleu TX-III PLA₂, injected in the footpad of mice. At various time intervals the increase in footpad volume, as compared to controls, was expressed as percent edema. Each point represents the mean ± SEM of five animals. (d), (e), and (f) Cytokines levels in mice. The production of IL-1, IL-6, and TNF-α was assayed in plasma of Bleu TX-III PLA₂. The experiments were performed in triplicate and analyzed statistically by ANOVA or Kruskal-Wallis tests and confirmed by Tukey and Tukey-type tests. Each point represents ±SEM of seven mice *P* < 0.05 between the experimental groups and control group.

in agreement with the reported compositions and primary structures of myotoxic PLA₂s isolated from *Bothrops* venoms [9, 21–23].

This basic PLA₂ showed enzymatic activity on monodisperse substrate, with a strict requirement of Ca²⁺, and maximum activity at pH 8.0 and 40°C. These characteristics are common to other bothropic and crotalic PLA₂s [21, 24, 25]. The PLA₂ activity is suggested to be higher in Bleu TX-III (16.22 ± 0.5268 nmols/mim) and *bl/D-49* (4) (15.728 ± 0.3354 nmols/min) when compared with the whole venom (3.617 ± 0.4144 nmols/min) and *bl/K-49* (2.856 ± 0.464 nmols/min) (Figure 1(c)). The Ca²⁺ ion dependent on the enzymatic activity of Bleu TX-III revealed that the Ca²⁺ ion is an obligatory cofactor for its enzymatic activity. This can be explained by different coordination geometries assumed by the tetrahedral intermediate due to the presence of the Ca²⁺ ion which determine the electrophilic behavior of the catalytic site, as well as stabilizes the otherwise flexible Ca²⁺-binding loop and appears to optimize the interaction enzyme substrate [26].

Comparison of the N-terminal sequence of Bleu TX-III showed similarity with other myotoxic PLA₂ from *Bothrops* genus (Figure 3).

To Bleu TX-III, no substitution was found in the conserved regions of the catalytic activity, as the channel hydrophobic N-terminal region (1 to 10) is important as a part of the interfacial bonding surface, so as active site (44 to 57) as suggested [26–28]. Considering the 7-peptides sequenced (this work), Bleu TX-III, showed high-level homology with many PLA₂, from different snakes species. The highly conserved sequences XCGXGG and DXCCXXHD responsible for the Ca²⁺-binding loop and the catalytic site of PLA₂ [29], respectively, are present in the sequence of PLA₂ Bleu TX-III.

The P3 (*bl/K-PLA₂*), P4 (*bl/D-PLA₂*), and fraction 5 (Bleu TX-III) enzymes seemed to be completely separated by reverse phase chromatography, and when some triptic peptides were sequenced by ESI/MS, of three PLA₂, venom showed that *Bothrops leucurus* have several homologous PLA₂ and PLA₂.

As a result of complications, mainly local edema and necrosis, usually occurred following ophidian accidents with *Bothrops* snakes [30, 31], and studies involving PLA₂s became very important, since they are the main venom components responsible for necrosis and inflammatory response [32].

Histological and ultrastructural studies of the effect of venom PLA₂s on skeletal muscle reveal a common series of pathological alterations which include (1) plasma membrane disruption, (2) formation of “delta-lesions,” wedge-shaped areas of degeneration located at the periphery of muscle fibers, (3) hypercontraction of myofilaments, (4) mitochondrial swelling, together with the formation of flocculent densities and rupture of mitochondrial membranes, (5) disruption of intracellular membrane systems, that is, sarcoplasmic reticulum and T tubules, and (6) pycnosis of nuclei [32–35].

Our studies on local and systemic myotoxicity *in vivo* show that PLA₂ Bleu TX-III is not systemic myotoxins in the

dose of 5 µg and 20 µg systemic slightly as local action due to decreased plasma levels of CK (Figures 4(a) and 4(b)). This reinforces the hypothesis of differential action of local and systemic myotoxicity proposed [32] and also the specificity and specificity proposed [21, 23, 28].

The snake venom *Bothrops* induced local edema in humans and experimental animals [36]. Besides Bleu TX-III, a number of snake venom PLA₂s, others also induce edema of 30 minutes after injection (Figure 3(c)) [4, 37, 38]. Studies have been conducted trying to understand the mechanisms involved in the inflammatory response induced by the myotoxic PLA₂ from several snake venoms [30]. Studies have been directed trying to understand the mechanisms involved in the inflammatory response induced by myotoxic PLA₂ from several snake venoms [39–41]. However, the relationship between enzymatic activity and edema is contradictory [42]. It is assumed that myotoxic and edematogenic activities can be induced by different structural domains in these PLA₂, or that a partial overlapping of these domains occur [43].

Cytokines, such as IL-1, IL-6, and TNF-α, are also relevant mediators for leukocyte migration and participate in several inflammatory conditions. Our results showed that PLA₂ Bleu TX-III induced a stronger effect on the expression of adhesion molecules by endothelial cells and stimulates the release of both IL-1, IL-6, and TNF-α [44]. Thus, our results suggest that IL-1 may contribute for the leukocyte (Figures 3(d), 3(e), and 3(f)).

In conclusion, Bleu TX-III induces a marked inflammatory reaction in the mouse serum. Since basic myotoxic PLA₂s are abundant in snake venoms, these toxins must play a relevant role in the proinflammatory activity that characterizes this venom. The fact that Bleu TX-III elicited a stronger reaction inflammatory argues in favor of a role of enzymatic phospholipid hydrolysis in this phenomenon, either through the direct release of arachidonic acid from plasma membranes or through the activation of intracellular processes in target cells.

Acknowledgments

The authors acknowledge the Mass Spectrometry Laboratory at Brazilian Biosciences National Laboratory, CNPEM-ABTLUS, Campinas, Brazil, for their support with the mass spectrometric analyses. They also thank Daniel Martins-de-Souza from Max Planck Institute of Psychiatry, Munich, Germany and Mr. Paulo A. Baldasso for general technical assistance. This work was supported by Capes and is a part of Mg Sc. thesis by F. A. Marangoni.

References

- [1] J. J. Calvete, “Venomics: digging into the evolution of venomous systems and learning to twist nature to fight pathology,” *Journal of Proteomics*, vol. 72, no. 2, pp. 121–126, 2009.
- [2] J. W. Fox and S. M. T. Serrano, “Exploring snake venom proteomes: multifaceted analyses for complex toxin mixtures,” *Proteomics*, vol. 8, no. 4, pp. 909–920, 2008.

- [3] D. Georgieva, R. K. Arni, and C. Betzel, "Proteome analysis of snake venom toxins: pharmacological insights," *Expert Review of Proteomics*, vol. 5, no. 6, pp. 787–797, 2008.
- [4] F. Chaves, G. León, V. H. Alvarado, and J. M. Gutiérrez, "Pharmacological modulation of edema induced by Lys-49 and Asp-49 myotoxic phospholipases A₂ isolated from the venom of the snake *Bothrops asper* (terciopelo)," *Toxicon*, vol. 36, no. 12, pp. 1861–1869, 1998.
- [5] D. C. S. Damico, S. Lilla, G. De Nucci et al., "Biochemical and enzymatic characterization of two basic Asp49 phospholipase A₂ isoforms from *Lachesis muta muta* (Surucucu) venom," *Biochimica et Biophysica Acta*, vol. 1726, no. 1, pp. 75–86, 2005.
- [6] R. Doley and R. M. Kini, "Protein complexes in snake venom," *Cellular and Molecular Life Sciences*, vol. 66, no. 17, pp. 2851–2871, 2009.
- [7] D. C. O. Nunes, R. S. Rodrigues, M. N. Lucena et al., "Isolation and functional characterization of proinflammatory acidic phospholipase A₂ from *Bothrops leucurus* snake venom," *Comparative Biochemistry and Physiology C*, vol. 154, no. 3, pp. 226–233, 2011.
- [8] D. A. Higuchi, C. M. V. Barbosa, C. Bincoletto et al., "Purification and partial characterization of two phospholipases A₂ from *Bothrops leucurus* (white-tailed-jararaca) snake venom," *Biochimie*, vol. 89, no. 3, pp. 319–328, 2007.
- [9] L. A. Ponce-Soto, P. A. Baldasso, F. F. Romero-Vargas, F. V. Winck, J. C. Novello, and S. Marangoni, "Biochemical, pharmacological and structural characterization of two PLA₂ isoforms Cdr-12 and Cdr-13 from *Crotalus durissus ruruima* snake venom," *Protein Journal*, vol. 26, no. 1, pp. 39–49, 2007.
- [10] H. Schagger and G. Von Jagow, "Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa," *Analytical Biochemistry*, vol. 166, no. 2, pp. 368–379, 1987.
- [11] M. Holzer and S. P. Mackessy, "An aqueous endpoint assay of snake venom phospholipase A₂," *Toxicon*, vol. 34, no. 10, pp. 1149–1155, 1996.
- [12] L. A. Ponce-Soto, M. H. Toyama, S. Hyslop, J. C. Novello, and S. Marangoni, "Isolation and preliminary enzymatic characterization of a novel PLA₂ from *Crotalus durissus collilineatus* venom," *Journal of Protein Chemistry*, vol. 21, no. 3, pp. 131–136, 2002.
- [13] R. L. Hendrickson and S. C. Meredith, "Amino acid analysis by reverse-phase high-performance liquid chromatography: pre-column derivatization with phenylisothiocyanate," *Analytical Biochemistry*, vol. 136, pp. 65–74, 1984.
- [14] J. H. Schumaker, A. OGarra, B. Schrader et al., "The characterization of four monoclonal antibodies specific for mouse IL-5 and development of mouse and human IL-5 ELISA," *The Journal of Immunology*, vol. 141, pp. 1576–1581, 1988.
- [15] M. R. Ruff and G. E. Gifford, "Purification and physico-chemical characterization of rabbit tumor necrosis factor," *Journal of Immunology*, vol. 125, no. 4, pp. 1671–1677, 1980.
- [16] T. R. John, L. A. Smith, and I. I. Kaiser, "Genomic sequences encoding the acidic and basic subunits of Mojave toxin: unusually high sequence identity of non-coding regions," *Gene*, vol. 139, no. 2, pp. 229–234, 1994.
- [17] H. M. Verheij, J. Westerman, B. Sternby, and G. H. de Haas, "The complete primary structure of phospholipase A₂ from human pancreas," *Biochimica et Biophysica Acta*, vol. 747, no. 1–2, pp. 93–99, 1983.
- [18] A. K. Calgarotto, D. C. S. Damico, L. A. Ponce-Soto et al., "Biological and biochemical characterization of new basic phospholipase A₂ BmTX-I isolated from *Bothrops moojeni* snake venom," *Toxicon*, vol. 51, no. 8, pp. 1509–1519, 2008.
- [19] E. Valentin and G. Lambeau, "What can venom phospholipases A₂ tell us about the functional diversity of mammalian secreted phospholipases A₂?" *Biochimie*, vol. 82, no. 9–10, pp. 815–831, 2000.
- [20] L. A. Ponce-Soto, V. L. Bonfim, L. Rodrigues-Simioni, J. C. Novello, and S. Marangoni, "Determination of primary structure of two isoforms 6-1 and 6-2 PLA₂ D49 from *Bothrops jararacussu* snake venom and neurotoxic characterization using in vitro neuromuscular preparation," *Protein Journal*, vol. 25, no. 2, pp. 147–155, 2006.
- [21] L. A. Ponce-Soto, J. C. Barros, S. Marangoni et al., "Neuromuscular activity of BaTX, a presynaptic basic PLA₂ isolated from *Bothrops alternatus* snake venom," *Comparative Biochemistry and Physiology C*, vol. 150, no. 2, pp. 291–297, 2009.
- [22] J. Gutiérrez and B. Lomonte, "Phospholipase A₂ myotoxins from *Bothrops* snake venoms," *Toxicon*, vol. 33, no. 11, pp. 1405–1424, 1995.
- [23] R. M. Kini, "Excitement ahead: structure, function and mechanism of snake venom phospholipase A₂ enzymes," *Toxicon*, vol. 42, no. 8, pp. 827–840, 2003.
- [24] S. Huancahuire-Vega, L. A. Ponce-Soto, D. Martins-de-Souza, and S. Marangoni, "Structural and functional characterization of brazilitoxins II and III (BbTX-II and -III), two myotoxins from the venom of *Bothrops brazili* snake," *Toxicon*, vol. 54, no. 6, pp. 818–827, 2009.
- [25] J. A. Pereañez, V. Núñez, S. Huancahuire-Vega, S. Marangoni, and L. A. Ponce-Soto, "Biochemical and biological characterization of a PLA₂ from crotoxin complex of *Crotalus durissus cumanensis*," *Toxicon*, vol. 53, no. 5, pp. 534–542, 2009.
- [26] D. L. Scott, S. P. White, Z. Otwinowski, W. Yuan, M. H. Gelb, and P. B. Sigler, "Interfacial catalysis: the mechanism of phospholipase A₂," *Science*, vol. 250, no. 4987, pp. 1541–1546, 1990.
- [27] R. K. Arni and R. J. Ward, "Phospholipase A₂—a structural review," *Toxicon*, vol. 34, no. 8, pp. 827–841, 1996.
- [28] L. A. Ponce-Soto, D. Martins-De-souza, and S. Marangoni, "Neurotoxic, myotoxic and cytolytic activities of the new basic PLA₂ isoforms BmjeTX-I and BmjeTX-II isolated from the *Bothrops marajoensis* (marajó lancehead) snake venom," *Protein Journal*, vol. 29, no. 2, pp. 103–113, 2010.
- [29] R. Renetseder, S. Brunie, B. W. Dijkstra, J. Drenth, and P. B. Sigler, "A comparison of the crystal structure of phospholipase A₂ from bovine pancreas and *Crotalus atrox* venom," *Journal of Biological Chemistry*, vol. 260, no. 21, pp. 11627–11634, 1985.
- [30] J. M. Gutiérrez, "Understanding snake venoms: 50 years of research in Latin America," *Revista De Biología Tropical*, vol. 50, no. 2, pp. 377–394, 2002.
- [31] A. S. Kamiguti, J. L. C. Cardoso, R. D. G. Theakston et al., "Coagulopathy and haemorrhage in human victims of *Bothrops jararaca* envenoming in Brazil," *Toxicon*, vol. 29, no. 8, pp. 961–972, 1991.
- [32] J. M. Gutiérrez and C. L. Ownby, "Skeletal muscle degeneration induced by venom phospholipases A₂: insights into the mechanisms of local and systemic myotoxicity," *Toxicon*, vol. 42, no. 8, pp. 915–931, 2003.
- [33] J. M. Gutierrez, C. L. Ownby, and G. V. Odell, "Skeletal muscle regeneration after myonecrosis induced by crude venom and

- a myotoxin from the snake *Bothrops asper* (Fer-de-Lance),” *Toxicon*, vol. 22, no. 5, pp. 719–731, 1984.
- [34] J. B. Harris and M. J. Cullen, “Muscle necrosis caused by snake venoms and toxins,” *Electron Microscopy Reviews*, vol. 3, no. 2, pp. 183–211, 1990.
- [35] D. Mebs and C. L. Ownby, “Myotoxic components of snake venoms: their biochemical and biological activities,” *Pharmacology and Therapeutics*, vol. 48, no. 2, pp. 223–236, 1990.
- [36] J. M. Gutiérrez, F. Chaves, and L. Cerdas, “Inflammatory infiltrate in skeletal muscle injected with *Bothrops asper* venom,” *Revista de Biología Tropical*, vol. 34, no. 2, pp. 209–214, 1986.
- [37] D. F. J. Ketelhut, M. Homem De Mello, E. L. G. Veronese et al., “Isolation, characterization and biological activity of acidic phospholipase A₂ isoforms from *Bothrops jararacussu* snake venom,” *Biochimie*, vol. 85, no. 10, pp. 983–991, 2003.
- [38] R. S. Rodrigues, L. F. M. Izidoro, S. S. Teixeira et al., “Isolation and functional characterization of a new myotoxic acidic phospholipase A₂ from *Bothrops pauloensis* snake venom,” *Toxicon*, vol. 50, no. 1, pp. 153–165, 2007.
- [39] E. C. T. Landucci, R. C. Castro, M. F. Pereira et al., “Mast cell degranulation induced by two phospholipase A₂ homologues: dissociation between enzymatic and biological activities,” *European Journal of Pharmacology*, vol. 343, no. 2-3, pp. 257–263, 1998.
- [40] E. C. T. Landucci, R. C. De Castro, M. Toyama et al., “Inflammatory oedema induced by the Lys-49 phospholipase A₂ homologue piratoxin-I in the rat and rabbit. Effect of polyanions and *p*-bromophenacyl bromide,” *Biochemical Pharmacology*, vol. 59, no. 10, pp. 1289–1294, 2000.
- [41] B. Lomonte, A. Tarkowski, and L. A. Hanson, “Host response to *Bothrops asper* snake venom. Analysis of edema formation, inflammatory cells, and cytokine release in a mouse model,” *Inflammation*, vol. 17, no. 2, pp. 93–105, 1993.
- [42] B. S. Vishwanath, R. M. Kini, and T. V. Gowda, “Characterization of three edema-inducing phospholipase A₂ enzymes from habu (*Trimeresurus flavoviridis*) venom and their interaction with the alkaloid aristolochic acid,” *Toxicon*, vol. 25, no. 5, pp. 501–515, 1987.
- [43] J. P. Zuliani, C. M. Fernandes, S. R. Zamuner, J. M. Gutiérrez, and C. F. P. Teixeira, “Inflammatory events induced by Lys-49 and Asp-49 phospholipases A₂ isolated from *Bothrops asper* snake venom: role of catalytic activity,” *Toxicon*, vol. 45, no. 3, pp. 335–346, 2005.
- [44] E. Stylianou and J. Saklatvala, “Interleukin-1,” *International Journal of Biochemistry and Cell Biology*, vol. 30, no. 10, pp. 1075–1079, 1998.